Notes: December 20, 2019 -- As previously disclosed, Protalix BioTherapeutics, Inc. (the “Company”) held a Special Meeting of Stockholders on December 9, 2019 (the “Meeting”). At the Meeting, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio not less than 1-for-10 and not greater than 1-for-20, and to reduce the total number of shares of the Company’s common stock that it is authorized to issue from 350 million shares to 120 million. The ratio was fixed by the Company’s Board of Directors prior to the meeting to be 1-for-10 (the “Reverse Stock Split”). The Company’s common stock is expected to begin trading on the NYSE American on a split-adjusted basis when the market opens on Friday, December 20, 2019 and on the Tel Aviv Stock Exchange (the “TASE”) on a split adjusted basis when the market opens on Sunday, December 22, 2019. The Company’s common stock will continue to trade on the NYSE American and the TASE under the symbol “PLX.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 74365A309.